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clipping of ruptured cerebral aneurysms: 18 year follow-up 
of the UK cohort of the International Subarachnoid 
Aneurysm Trial (ISAT)
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Summary
Background Previous analyses of the International Subarachnoid Aneurysm Trial (ISAT) cohort have reported on the 
risks of recurrent subarachnoid haemorrhage and death or dependency for a minimum of 5 years and up to a 
maximum of 14 years after treatment of a ruptured intracranial aneurysm with either neurosurgical clipping or 
endovascular coiling. At 1 year there was a 7% absolute and a 24% relative risk reduction of death and dependency in 
the coiling group compared with the clipping group, but the medium-term results showed the increased need for re-
treatment of the target aneurysm in the patients given coiling. We report the long-term follow-up of patients in this 
UK cohort.
Methods In ISAT, patients were randomly allocated to either neurosurgical clipping or endovascular coiling after a 
subarachnoid haemorrhage, assuming treatment equipoise, between Sept 12, 1994, and May 1, 2002. We followed up 
1644 patients in 22 UK neurosurgical centres for death and clinical outcomes for 10·0–18·5 years. We assessed 
dependency as self-reported modiﬁ ed Rankin scale score obtained through yearly questionnaires. Data for recurrent 
aneurysms and rebleeding events were collected from questionnaires and from hospital and general practitioner 
records. The Oﬃ  ce for National Statistics supplied data on deaths. This study is registered, number ISRCTN49866681.
Findings At 10 years, 674 (83%) of 809 patients allocated endovascular coiling and 657 (79%) of 835 patients allocated 
neurosurgical clipping were alive (odds ratio [OR] 1·35, 95% CI 1·06–1·73). Of 1003 individuals who returned a 
questionnaire at 10 years, 435 (82%) patients treated with endovascular coiling and 370 (78%) patients treated with 
neurosurgical clipping were independent (modiﬁ ed Rankin scale score 0–2; OR 1·25; 95% CI 0·92–1·71). Patients in 
the endovascular treatment group were more likely to be alive and independent at 10 years than were patients in the 
neurosurgery group (OR 1·34, 95% CI 1·07–1·67). 33 patients had a recurrent subarachnoid haemorrhage more than 
1 year after their initial haemorrhage (17 from the target aneurysm). 
Interpretation Although rates of increased dependency alone did not diﬀ er between groups, the probability of death 
or dependency was signiﬁ cantly greater in the neurosurgical group than in the endovascular group. Rebleeding was 
more likely after endovascular coiling than after neurosurgical clipping, but the risk was small and the probability of 
disability-free survival was signiﬁ cantly greater in the endovascular group than in the neurosurgical group at 10 years.
Funding UK Medical Research Council.
Introduction
Since the introduction of endovascular coiling of 
ruptured cerebral aneurysms in 1990 in the USA and in 
1992 in Europe, concerns have been expressed about the 
durability of endovascular coiling and the degree of 
angiographic occlusion of the aneurysm (believed to be a 
surrogate marker for risk of recurrent subarachnoid 
haemorrhage [rebleeding from the aneurysm]). The 
International Subarachnoid Aneurysm Trial (ISAT) was a 
multicentre, randomised controlled trial, funded 
principally by the UK Medical Research Council, that 
enrolled 2143 patients with ruptured intracranial 
aneurysms in 43 centres. The trial aimed to assess the 
relative safety and eﬃ  cacy of endovascular coiling 
treatment versus neurosurgical clipping in patients who 
were suitable for either treatment. The primary objective 
was to establish the clinical outcomes at 1 year. The 
secondary objective was to assess diﬀ erences between 
the two treatments in the prevention of rebleeding from 
the treated aneurysm. The tertiary objective, reported 
here, was to obtain long-term follow-up data.
The trial methods and the 1 year primary outcomes 
have been published previously.1,2 The primary outcome 
(death or dependency at 1 year) showed that endovascular 
coiling resulted in signiﬁ cantly fewer dead and dependent 
patients than did neurosurgical clipping. The medium-
term results (secondary objective) showed that the 
endovascular group needed more frequent retreatment 
of the target aneurysm than did the neurosurgical group 
(late retreatment deﬁ ned as later than 1 month after the 
original subarachnoid haemorrhage for neurosurgery 
and later than 3 months after the original subarachnoid 
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haemorrhage for endovascular treatment3). However, 
these additional treatments had no detrimental eﬀ ect on 
dependency status in patients or on clinical outcome.4 In 
this Article, we report long-term follow-up data (tertiary 
objectives) for the 1644 patients enrolled in UK centres 
with 19 216 patient-years of follow-up.
Methods
Patients
Between Sept 12, 1994, to May 1, 2002, ISAT investigators 
enrolled 2143 patients with ruptured intracranial 
aneurysms at 43 centres, mostly in the UK, the rest of 
Europe, and Canada. Patients with ruptured intracranial 
aneurysms were randomly allocated to either 
neurosurgical clipping (n=1070) or endovascular coiling 
(n=1073). Patients were enrolled who had an aneurysm 
anatomically suitable for either treatment, in whom 
clinical equipoise existed for the best treatment, and in 
whom appropriate consent of the patient or assent of 
relatives could be obtained. The UK cohort was enrolled 
from 22 participating neurosurgical centres that 
provided both neurosurgical and endovascular 
treatment for acute subarachnoid haemorrhage from 
ruptured aneurysms. The methods of the trial have 
been described in detail in the published protocol and in 
the previous reports.1,2
From the very beginning of ISAT to adoption by the 
Medical Research Council and the publication of its results, 
the study has adhered to the strict standards and procedures 
for the conduct, design, and reporting of clinical trials, as 
laid out in the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines.5,6 After challenges to the published 
results, the investigators have remained true to the protocol 
and the analysis of the data by intention to treat, showing 
the everyday reality of working with patients who have a 
ruptured cerebral aneurysm.
Procedures
Every year, between the date of enrolment and May, 2012, 
we sent all surviving ISAT patients in the UK a postal 
questionnaire that assessed their dependency status, 
whether they had any further hospital admissions, and 
whether they had undergone any further treatment 
related to their subarachnoid haemorrhage or original 
aneurysm treatment. Patients who completed the annual 
questionnaire used the self-reported modiﬁ ed Rankin 
scale (mRS) and were followed up for a minimum of 
10 years. All UK patients were ﬂ agged with the Oﬃ  ce for 
National Statistics (ONS; now known as the Health and 
Social Care Information Centre). The Oxford Neurovascular 
and Neuroradiology Research Unit automatically received 
notiﬁ cation of the death of patients registered in the study. 
The Oxford unit collected data for all suspected instances 
of recurrent subarachnoid haemorrhage from information 
given by patients or their families on the questionnaires, 
after notiﬁ cation by the centre or the patient’s family 
doctor, or from information on the ONS notiﬁ cations. Data 
for recurrent subarachnoid haemorrhage were collected, 
including date, any hospital records, operative reports, 
imaging data, autopsy reports (when available), and death 
certiﬁ cates. An experienced neurosurgeon and neuro-
radiologist (RSCK and AJM) reviewed these records. All 
UK centres obtained local ethical committee approval for 
the study before enrolling patients.
Outcomes
We aimed to assess rates of death, dependence (measured 
according to patient-reported modiﬁ ed Rankin scale 
scores), and recurrent subarachnoid haemorrhage after 
neurosurgical clipping or endovascular coiling as part of 
the tertiary objectives of ISAT.
Statistical analysis
Survival analyses were done for time to rebleeding and for 
time to death, which was measured from the time of 
the initial subarachnoid haemorrhage. We censored 
observations in the analysis of time to rebleeding when a 
patient was lost to follow-up or had died. For the analysis of 
time to death, we retrieved all deaths among the UK cohort 
to a maximum of 18·5 years via ONS ﬂ agging. We extracted 
data for survival on March 31, 2013. We extracted data for 
dependency and rebleeding analyses on May 31, 2012, 
which had a maximum of 17·6 years follow-up. We 
calculated Kaplan-Meier curves for each treatment group, 
and the groups were compared using the log-rank test.
We calculated the standardised mortality ratio as the 
ratio of deaths recorded to deaths expected based on 
age and sex stratiﬁ cation, as reported in the UK interim 
life tables from ONS,7 conditional on 1 year survival. 
A two-tailed probability value of less than 0·05 and 
non-overlapping conﬁ dence intervals were used to 
judge statistical signiﬁ cance.
To calculate the standardised mortality ratio, we 
included all deaths of patients from 1 year after 
subarachnoid haemorrhage until Dec 31, 2012. We used 
standard death rates for England and Wales, which 
covered 5 year age bands for individuals aged 15–24 years, 
10 year age bands for individuals aged 25–85 years, and 
an age band for individuals older than 85 years, for all 
years from 1998 until 2012. We ascertained the number of 
patients alive on Jan 1, each year, at least 1 year from the 
date of their initial subarachnoid haemorrhage, and we 
counted the number of deaths during the year. The age of 
each patient was assessed as though at the mid-point 
of each year (July 1). We calculated the expected number of 
deaths for each year and summed them for all years.
To compare rates of low severity self-reported mRS 
scores (0–2) at 10 years between the treatment groups, 
we extracted the results of the tenth annual question-
naire, together with the absolute numbers of deaths 
before 10 years after subarachnoid haemorrhage. The 
probability of a good outcome at 10 years is the 
probability of a good score on the self-reported mRS 
multiplied by the probability of being alive at 10 years. 
For the Health and Social Care 
Information Centre see 
http://www.hscic.gov.uk
Articles
www.thelancet.com   Vol 385   February 21, 2015 693
These probabilities have diﬀ erent denominators; we 
calculated the death rate with the complete UK cohort 
and estimated the score on the Rankin scale only in 
individuals not lost to follow-up and who returned the 
annual questionnaire. We calculated the SE for the 
probability of a good mRS score and of being alive (a 
good outcome) with the delta method (not shown). 
Similarly, we calculated the SE and 95% CI for the odds 
ratio (OR) of a good outcome for the treatment groups 
with the delta method.
We did sensitivity analyses, replacing missing 10-year 
mRS scores with 11 year, 9 year, or 8 year scores, in that 
order, when available, for the calculation of the probability 
of a good mRS and of being alive at 10 years after 
subarachnoid haemorrhage. Finally, we repeated the 
calculation with the latest available mRS score for 
patients alive at 10 years after subarachnoid haemorrhage 
but who had a missing score at 8, 9, 10, and 11 years. We 
did all analyses with Stata version 12. This study is 
registered, number ISRCTN49866681.
Role of the funding source
The trial was designed, completed, and analysed inde-
pendently of the funders. The chief investigators (RSCK 
and AJM) had full access to all the data in the study and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
As of March 31, 2013, 1256 (76%) of 1644 patients enrolled 
in ISAT from UK centres were still alive. We followed up 
these patients for a minimum of 10·0 years and a maximum 
of 18·5 years (19 216 patient-years). 10 years after their 
original subarachnoid haemorrhage, 1331 (80%) of the 
1644 patients had survived (table 1). Ten patients were lost 
to follow-up after the 2 month questionnaire. 1283 people 
returned questionnaires at 5 years or later. Thus, we had 
good follow-up from 1283 (96%) of 1331 of the cohort who 
lived for 10 years and some follow-up from 1321 (99%) of 
1331 of the whole UK cohort.
1003 (75%) patients returned a questionnaire at 10 years 
(table 1). The proportion of patients with a good mRS score 
(0–2) did not diﬀ er between endovascular and neurosurgery 
groups (table 1). The probability of being alive with a good 
outcome (mRS 0–2) compared with death or dependence 
was signiﬁ cantly better for the group allocated endovascular 
treatment than for those allocated neurosurgical clipping 
(table 1). 
In our sensitivity analysis, we retrieved mRS values 
from questionnaires done at years 11, 9, and 8 to replace 
missing values in records at year 10. Data were available 
Survival at 10 years Independence at 10 years Independent survival at 10 years
Alive Dead OR (95% CI) mRS score 0–2 mRS score 3–5 OR (95% CI) Probability of 
independent 
survival*
OR (95% CI)
Endovascular coiling group 674/809 (83%) 135/809 (17%) 1·35 (1·06–1·73) 435/531 (82%) 96/531 (18%) 1·25 (0·92–1·71) 0·682 1·34 (1·07–1·67)
Neurosurgical clipping group 657/835 (79%) 178/835 (21%) Ref 370/472 (78%) 102/472 (22%) Ref 0·617 Ref 
Data are n/N with available data (%), unless otherwise stated. OR=odds ratio. mRS=modiﬁ ed Rankin scale. *Calculated by multiplication of probability of being alive and probability of good mRS (0–2).
Table 1: Death and dependency at 10 years
Rebleeding from 
target aneurysm* 
(deaths)
Rebleeding from 
aneurysm known at 
baseline† (deaths)
De-novo 
aneurysm‡ 
(deaths)
Aneurysm from 
unknown source 
(deaths)
Total
Endovascular coiling group (8351 patient-years) 13 (3) 4 (2) 3 (1) 1 (1) 21 (7)
Neurosurgical clipping group (8228 patient-years) 4 (2) 2 (2)§ 6 (3) 0 12 (7)
Total 17 (5) 6 (4) 9 (4) 1 (1) 33 (14)
Numbers for UK patients as of May 31, 2012. Numbers in parentheses show deaths within 30 days of rebleeding. *Aneurysm identiﬁ ed at the time of enrolment in the trial 
(log-rank p=0·02; ﬁ gure 1). †Other known aneurysm present on the ﬁ rst angiogram but not believed to have ruptured. ‡Aneurysms not shown on the ﬁ rst angiogram. 
§One patient died at 48 days from recurrent subarachnoid haemorrhage.
Table 2: Number of patients who had recurrent subarachnoid haemorrhage after 1 year 
Figure 1: Kaplan-Meier plot of cumulative risk of rebleeding from target 
(treated) aneurysm later than 1 year after subarachnoid haemorrhage
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for 1200 (90%) of 1331 patients alive after 10 years. The 
proportion of patients with a good mRS score was 81% 
(503 of 620 individuals) in the endovascular group and 
78% (450 of 580 individuals) in the neurosurgical group 
(OR 1·24, 95% CI 0·93–1·65). In this analysis, the 
probability of a good clinical outcome (being alive and 
mRS 0–2) compared with death or dependence for the 
two  groups favoured the endovascular group (OR 1·33, 
95% CI 1·08–1·65). Finally, we replaced missing values 
with the latest available mRS score, including the 2 month 
mRS score for the ten patients who were lost to follow-up 
before the ﬁ rst year questionnaire. The proportion of 
patients with a good mRS score was 81% (546 of 674) in 
the endovascular group, and 77% (504 of 657) in the 
neurosurgical group (OR 1·29, 95% CI 0·99–1·70). 
The probability of a good clinical outcome rather than 
death or dependence again favoured the endovascular 
group (OR 1·36, 95% CI 1·11–1·68).
All data for recurrent subarachnoid haemorrhage that 
occurred before 1 year of follow-up have been reported 
previously, therefore we only report data for patients who 
had a recurrent subarachnoid haemorrhage later than 1 year 
after their initial haemorrhage.2 33 patients had a recurrent 
subarachnoid haemorrhage (table 2). Rebleeding from the 
target aneurysm (the aneurysm identiﬁ ed as ruptured at the 
time of enrolment) occurred in 17 patients, whereas the 
other 16 patients rebled from another source. At end of 
follow-up, the cumulative risk of a rebleed from the target 
aneurysm was 0·0216 (95% CI 0·0121–0·0383) for patients 
in the endovascular group and 0·0064 (0·0024–0·0173) for 
patients in the neurosurgery group (ﬁ gure 1).
13 patients in the endovascular group rebled from the 
target aneurysm (between 1·9 years and 13·2 years after 
the procedure), and three of these individuals died within 
30 days (table 2, appendix). Of the remaining ten patients, 
seven were independent at end of follow-up. Incidence 
of recurrent subarachnoid haemorrhage was one in 
641 patient-years (table 3). In the neurosurgical group, 
rebleeding occurred in four patients (timing between 
6·1 and 11·4 years), resulting in two deaths within 30 days 
of the event. Incidence was one in 2041 patient-years. The 
risk of having a poor outcome (death or mRS score ≥3) 
from this recurrent subarachnoid haemorrhage was 
one in 1397 patient-years in the endovascular group and 
one in 2041 patient-years for the neurosurgery group.
Of the 16 patients that rebled from another source, 
15 bled from another aneurysm (table 2, appendix). 
Six bled from a pre-existing aneurysm that had been 
identiﬁ ed on angiogram at the time of presentation with 
the original subarachnoid haemorrhage and nine bled 
from a new aneurysm that was not present or reported 
on the initial angiogram. In one patient, it was not 
possible to determine the source of the rebleed.
Investigators have previously summarised data for 
deaths and causes of deaths from 2 months after random-
isation to 14 years, with a mean of 9 years follow-up.2,3 
During the 18·5 year follow-up period, 388 (24%) patients 
died in the UK cohort (ﬁ gure 2). Of the six deaths due to 
recurrent subarachnoid haemorrhage from the target 
aneurysm after 1 year, four were in the endovascular 
groups and two in the neurosurgical group (table 4). Over 
the same time period (up to March 31, 2013), nine deaths 
were due to rupture of another aneurysm. 249 deaths 
occurred later than 1 year after the initial haemorrhage, of 
which 232 were not related to cerebral aneurysms or the 
previous subara chnoid haemorrhage; most were due to 
cancer and cardiovascular disease (table 5). There were 
signiﬁ cantly more deaths in the survivors in both groups 
than in the general age-matched population.
Discussion
In this study, we provide long-term data for clinical 
outcomes after treatment of subarachnoid haemorrhage 
(panel). Since the introduction of endo vascular coiling of 
ruptured cerebral aneurysms, concern has been expressed 
about the long-term durability of the treatment, and its 
ability to prevent recurrent subara chnoid haemorrhage. 
Coiling compared with clipping improves short-term and 
medium-term clinical outcomes for selected patients with 
ruptured aneurysms; proven to class one level A evidence.8 
Patients were enrolled in ISAT soon after the introduction 
of aneurysm coiling, ﬁ rst used in the UK in 1992. There is 
See Online for appendix
Number of patients Total patient-years Incidence per 1000 patient-years
Number of rebleeds*
Endovascular group 13 8351 1·56 (0·69–2·40)
Neurosurgery group 4 8228 0·49 (0.01–0.96)
Death and disability due to rebleed†
Endovascular group 6 8384 0·72 (0·14–1·29)
Neurosurgery group 4 8228 0·49 (0·01–0·96)
Data in parentheses are 95% CI. *Rebleeds from target aneurysm assessed from 1 year up to 17·6 years’ of follow-up in 
the UK population. †Rebleeds from target aneurysm resulting in death within 60 days or score of 3–5 on the modiﬁ ed 
Rankin scale.
Table 3: Incidence of recurrent subarachnoid haemorrhage from target aneurysm and of resulting death 
or disability (mRS 3–5)
Figure 2: Kaplan-Meier plot of cumulative mortality
Patients observed for 10–18·5 years in 22 UK centres.
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a growing body of evidence that suggests that the clinical 
outcome after coiling ruptured aneurysms has improved 
compared with that in the ISAT enrolment period. Its 
eﬀ ectiveness to prevent early rebleeding also seems to 
have improved.9,10
The results of ISAT apply to those patients who were 
eligible for the study. The original criteria for enrolment 
were patients with proven ruptured aneurysms in whom 
clinical equipoise existed as to whether clipping or coiling 
was the best treatment and who had aneurysms that were 
judged anatomically suitable for endovascular coiling and 
surgical clipping. There was widespread criticism of the 
external validity of ISAT, particularly among clinicians in 
USA, based on the low proportion of patients enrolled 
(about 22% overall) in participating centres. This low 
number could have led to selection bias. In practice, the 
proportion of patients enrolled varied widely between 
participating centres (from about 50% to less than 2% of all 
patients), showing the wide variations in the clinical 
equipoise of individual clinicians, mostly neurosurgeons.11 
In ISAT, the patient population that was represented was 
the most common group of patients treated for ruptured 
aneurysms. 88% of enrolled patients were in good clinical 
grade (World Federation of Neurosurgical Societies grade 1 
or 2) with anterior circulation aneurysms smaller than 
10 mm. When compared with the demographics of 
patients treated after subarachnoid haemorrhage in the 
UK National Audit done by the Royal College of Surgeons,12 
81% of patients in 2001–02 had similar demographics to 
patients in ISAT. In an audit of subarachnoid haemorrhage 
treatment in the UK over a 5 month period in 2011,13 85% 
of patients treated for ruptured aneurysms had coiling. We 
think that the results apply to most patients with a ruptured 
cerebral aneurysm. With the improved coil devices and 
techniques that are now available, most ruptured cerebral 
aneurysms are anatomically suitable for coiling.
Concern has remained, quite reasonably, about 
whether beneﬁ ts for the endovascular treatment might 
be lost in the long-term because of an increased risk of 
rebleeding and complications associated with further 
treatment. Our data lend support to a small excess risk of 
recurrent subarachnoid haemorrhage from the target 
aneurysm in the endovascular group up to 17·6 years 
after the initial haemorrhage; however, this excess did 
not translate to a signiﬁ cantly worse clinical outcome 
when compared with that of the surgically treated group. 
The overall risk of death or dependency from a rebleed 
did not diﬀ er between the groups.
In the UK we were able to examine the long-term 
mortality risk of patients by prospectively ﬂ agging 
patients with the ONS. This process has enabled reliable 
2–12 months 1–5 years After 5 years
Endovascular 
(n=762)*
Neurosurgery 
(n=768)*
Endovascular 
(n=753)†
Neurosurgery 
(n=752)†
Endovascular 
(n=733)‡
Neurosurgery 
(n=719)‡
Complication of severely dependent survival (chest or other 
infections)
6 13 0 2 0 0
Cancer 0 0 6 13 37 25
Cardiac¶ 0 0 2 7 19 20
Recurrent SAH from treated target aneurysm 1 1 0 0 4§ 2
Recurrent SAH from another known, unknown, or de-novo 
aneurysm
0 0 3 1 1 4
Other intracranial haemorrhage 0 0 1 0 2 3
Ischaemic stroke 0 0 2 3 3 5
Suicide 0 1 1 0 1 0
Renal failure 1 0 0 1 3 2
Infections not related to dependent survival 0 1 2 3 6 2
Respiratory complications 0 0 2 2 17 11
Other|| 0 0 1 0 10 16
Unknown 1 0 0 1 2 1
Total 9 16 20 33 105 91
Shows all UK deaths to March 31, 2013. SAH=subarachnoid haemorrhage. *Number of patients alive at 2 months. †Number of patients alive at 1 year. ‡Number of patients 
alive at 5 years. §One patient died from residual complications 3 years after recurrent SAH. ¶Cardiac causes are cardiac arrest, coronary artery disease, ischaemic heart disease, 
and myocardial infarction. ||Other includes trauma, perforated ulcer, pulmonary embolus, and neurodegenerative disease. 
Table 4: Causes of death in all UK patients from 2 months after enrolment
Deaths Expected deaths Standardised mortality ratio (95% CI)
All patients 246 175 1·40 (1·23–1·58)
Women 146 106 1·37 (1·15–1·59)
Men 100 69 1·45 (1·17–1·73)
Endovascular group 122 89 1·37 (1·13–1·62)
Neurosurgery group 124 87 1·43 (1·18–1·67)
Calculated using deaths of all UK patients up to Dec 31, 2012. 
Table 5: Standardised mortality ratios
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data for death to be collected for the entire UK ISAT 
cohort. Long-term causes of death in surviving patients 
were largely unrelated to the subarachnoid haemorrhage 
and were mainly due to other reasons (mostly cancer and 
cardiovascular disease). Patients were 40-times more 
likely to die from another cause than from the treated 
aneurysm. This ﬁ gure emphasises the importance of 
lifestyle advice, particularly about smoking cessation and 
management of hypertension.
A substantial portion of the UK ISAT patients have 
continued to return their annual questionnaires; analysis 
of these data show that the noted short-term and 
medium-term clinical beneﬁ t of endovascular coiling 
remains signiﬁ cant in the long term. Furthermore, 
sensitivity analysis shows that the 10-year mRS was not 
biased by missing values, which seem to be random. 
Little diﬀ erence existed between 5-year and 10-year 
dependency status for individuals.
The main strength of our study is that it represents a 
unique, prospectively enrolled population with complete 
ascertainment of death rates for up to 18 years, and very 
low loss of data for clinical outcome at 10 years. Thus, 
we believe that this dataset will be the best available for 
the long-term risks for patients treated for ruptured 
cerebral aneurysms. However, the long-term follow-up 
is limited to the UK cohort for cost and logistical 
reasons. Nevertheless, long-term durability of treatment 
will probably be similar between UK and non-UK 
patients who are given endovascular coiling. The coils 
and techniques and equipment are the same worldwide.
Another limitation of the study is the absence of imaging 
follow-up, which would have enabled correlation of 
angiographic ﬁ ndings after coiling with the rebleeding 
risk. We were also unable to assess how frequently and for 
how long patients should be assessed with imaging 
surveillance after coiling of an aneurysm. This question 
will be the subject of modelling in another study using 
these data, but, given the very low late risk of rebleeding, 
such long-term follow-up does not seem justiﬁ ed.
ISAT was a landmark international randomised 
controlled trial within the neurosurgical and neuro-
interventional communities. The results of the trial 
have changed clinical practice, with 85% of UK patients 
who have a ruptured aneurysm undergo coiling.13 
Furthermore, our results also lead us to question the 
beneﬁ t of continued surveillance of treated aneurysms, 
in view of the extremely low event rate noted in the 
treated population, which has now been followed up for 
18 years. 
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